AbbVie (ABBV) AI Analysis

ABBV$294.98+1.09 +0.37%
Drug Manufacturers - GeneralMega CapHigh Quality
Compare
Market cap$521.41BEnterprise value$591.13BRevenue (TTM)$66.01BMarket positionTop 5%

Score

56
Neutral
Value
35
Quality
73
Growth
59

AI Score 70. AbbVie Inc. has a strong market capitalization of $505.4 billion and a solid gross profit margin of approximately 76.3%

Summary

AbbVie Inc. operates in the Healthcare sector and Drug Manufacturers - General industry. The company reports a net margin of 15.7% and a dividend yield of 2.4%.

Valuation

The shares trade at a P/E ratio of 50.6, which is a key valuation input but cannot be assessed against peers or history from the provided facts. Price-to-book is -88.0, limiting its usefulness as a conventional valuation measure.

Quality

A net margin of 15.7% indicates the company generated positive reported profitability. The negative price-to-book figure of -88.0 suggests book-value-based analysis requires caution.

Growth

No revenue, earnings-growth, estimate-revision, or price-trend data is provided. Growth cannot be evaluated from the available facts.

Risks

The P/E ratio of 50.6 may leave the shares sensitive to changes in earnings expectations. Negative price-to-book of -88.0 also makes balance-sheet valuation interpretation less straightforward.

AbbVie (ABBV) AI Analysis

ABBV price $294.98 +1.09 +0.37%

Ticker
ABBV
Price
$294.98
Change
+1.09 +0.37%
Market cap
$521.41B
P/E
50.50
Dividend yield
2.35%
Beta
0.28
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
56
Value
35
Quality
73
Growth
59

Stocklytics score rationale: value 35, quality 73, growth 59.

AI Score 70. AbbVie Inc. has a strong market capitalization of $505.4 billion and a solid gross profit margin of approximately 76.3%

Summary

AbbVie Inc. operates in the Healthcare sector and Drug Manufacturers - General industry. The company reports a net margin of 15.7% and a dividend yield of 2.4%.

Valuation

The shares trade at a P/E ratio of 50.6, which is a key valuation input but cannot be assessed against peers or history from the provided facts. Price-to-book is -88.0, limiting its usefulness as a conventional valuation measure.

Quality

A net margin of 15.7% indicates the company generated positive reported profitability. The negative price-to-book figure of -88.0 suggests book-value-based analysis requires caution.

Growth

No revenue, earnings-growth, estimate-revision, or price-trend data is provided. Growth cannot be evaluated from the available facts.

Risks

The P/E ratio of 50.6 may leave the shares sensitive to changes in earnings expectations. Negative price-to-book of -88.0 also makes balance-sheet valuation interpretation less straightforward.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener